



CELLERANT THERAPEUTICS

FOR IMMEDIATE RELEASE

CELLERANT THERAPEUTICS PRESENTS PRECLINICAL DATA DEMONSTRATING THERAPEUTIC BENEFIT OF EXPANDED MYELOID PROGENITORS AT 2005 TANDEM BMT MEETINGS

PALO ALTO, Calif. – February 14, 2005 – Cellerant Therapeutics, Inc. today presented preclinical proof-of-concept data for its expanded myeloid progenitor cell (MP) program at the ASBMT/CIBMTR 2005 Tandem BMT Meetings. In preclinical studies, Cellerant’s MP cell product resulted in a survival benefit in immune-compromised mice exposed to lethal fungal infections.

“These experiments lay the foundation for Cellerant’s myeloid progenitor product program: a cell product that can be manufactured and given to patients like a drug, without the kind of immunologic matching that currently limits cell therapy,” stated Dr. Timothy Fong, Vice President of Research at Cellerant. “Cellerant is pleased to present these data to the blood and marrow transplant community, as we believe the myeloid progenitor product represents a potential leap forward in the treatment of BMT patients as well as other patients at risk from neutropenia.”

About Myeloid Progenitor Cells

All of the mature cells of the blood and immune systems are derived from hematopoietic (blood-forming) stem cells (HSCs). These stem cells differentiate into more mature progenitor cells and eventually mature cells. Myeloid progenitor cells are progenitors which have differentiated from HSCs and can further differentiate to become various mature cell types, including red blood cells, platelets, or infection-fighting cells called neutrophils. Freshly isolated myeloid progenitor cells (MPs) have been shown in previous work by Dr. Wes Brown of Stanford University to protect mice with neutropenia (a life-threatening lack of neutrophils) from lethal opportunistic infections by bacteria and fungi.

About the Study

Using Cellerant’s proprietary method, HSCs were harvested from mice and cultured *ex vivo* to manufacture large numbers of MPs. The manufactured MPs demonstrated equivalent or better activity compared to freshly isolated MPs in an established model of bone marrow transplantation with infectious complications. Additionally, these experiments established that expanded MPs derived from unmatched donor mice were effective in providing protection, even with significant immunologic mismatch between donor and host.

About the 2005 Tandem BMT Meetings

The 2005 Tandem BMT Meetings are the joint meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplantation (CIBMTR, formerly IBMTR/ABMTR), and is the largest annual meeting of blood and marrow transplant specialists from around the world.

About Cellerant Therapeutics

Cellerant Therapeutics Inc. (www.cellerant.com) is a clinical-stage biotechnology company developing and commercializing the use of hematopoietic (blood-forming) stem cell-based products and therapies for the treatment of autoimmune and blood disorders, infectious disease and cancer. The company's extensive portfolio of intellectual property and clinical assets are licensed from Novartis AG and Stanford University. Cellerant has exclusive rights to the Highly Purified HSC cell population and process, the subject of more than fifteen issued U.S. and foreign patents, and the MP cell population and process, the subject of two issued U.S. patents and several pending U.S. and foreign patent applications.

For more information, please contact:

Chuck Dubuque
Corporate Development Manager
Cellerant Therapeutics, Inc.
(650) 842-0604
cdubuque@cellerant.com

Kari Lampka
MacDougall BioCommunications, Inc.
(508) 647-0209
kari@macbiocom.com

###